z-logo
open-access-imgOpen Access
Anti‐nuclear antibodies of primary biliary cirrhosis recognize 78–92‐kD and 96–100‐kD proteins of nuclear bodies
Author(s) -
FUSCONI M.,
CASSANI F.,
GOVONI M.,
CASELLI A.,
FARABEGOLI F.,
LENZI M.,
BALLARDINI G.,
ZAULI D.,
BIANCHI F. B.
Publication year - 1991
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/j.1365-2249.1991.tb05630.x
Subject(s) - primary biliary cirrhosis , antibody , immunofluorescence , western blot , anti nuclear antibody , nuclear protein , microbiology and biotechnology , autoantibody , pathology , biology , biliary cirrhosis , immunology , chemistry , medicine , autoimmune disease , biochemistry , transcription factor , gene
SUMMARY The specificities of anti‐nuclear antibodies (ANA) reacting with multiple nuclear dots (MND‐ANA) present in about 15% primary biliary cirrhosis sera were studied by Western blot analysis with nuclear fractions from a human cell line. Reactivity with two broad bands of 78–92 kD and 96–00 kD of the insoluble fraction was present exclusively in MND‐ANA‐positive sera. Antibodies eluted from these proteins specifically retained the immunofluorescence reactivity of MND‐ANA. Immunomorphological analysis by a pre‐embedding technique revealed that the antibody specifically binds to nuclear regions resembling in size and number nuclear bodies. Since these structures are absent in immature rate endometrial cell and can be induced by diethylstilbestrol. we tested MND‐ANA by immunofluorescence on cryostat sections of uteri from hormone‐treated and untreated immature rats. A strong reaction of nuclear dots was observed predominantly in endometrial cells of hormone treated rats. We thus conclude that MND‐ANA present in primary biliary cirrhosis sera are directed against 78–92‐kD and 96–100‐kD nuclear proteins located in nuclear bodies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here